Nicotine ( DrugBank: Nicotine )

3 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
6	パーキンソン病	9
13	多発性硬化症／視神経脊髄炎	1
84	サルコイドーシス	2

6. パーキンソン病

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03865121 (ClinicalTrials.gov)	March 4, 2019	26/2/2019	Pilot Trial of Transnasal Nicotine in Parkinson Disease	Uncontrolled Pilot Trial of Transnasal Nicotine in Parkinson Disease	Parkinson Disease	Drug: Nicotine Nasal Spray 10 MG/ML (0.5 MG/SPRAY)	El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez	Howard University	Completed	60 Years	N/A	All	6	Phase 2	Mexico
2	NCT02452125 (ClinicalTrials.gov)	May 2015	20/5/2015	The Effects of Nicotine Chewing Gum in Parkinson's Disease	The Effects of Nicotine Chewing Gum on Acute Low Blood Pressure in Parkinson's Disease	Low Blood Pressure;Parkinsons Disease	Dietary Supplement: Nicotine gum	New York Institute of Technology	NULL	Completed	N/A	N/A	All	10	N/A	United States
3	JPRN-UMIN000016664	2015/03/01	01/03/2015	Effect of nicotine patch in Cognitive function improvement in Parkinson's disease	Effect of nicotine patch in Cognitive function improvement in Parkinson's disease - Effect of nicotine patch in Cognitive function improvement	Parkinson's disease	nicotine patch	Department of Clinical Pharmacology and Neurology Ehime University graduated School of Medicine	NULL	Recruiting	Not applicable	Not applicable	Male and Female	20	Not selected	Japan
4	NCT01560754 (ClinicalTrials.gov)	October 2012	9/3/2012	Disease-modifying Potential of Transdermal NICotine in Early Parkinson's Disease	A Randomized, Placebo-controlled, Double-blind, Multi-center Trial to Assess the Disease-modifying Potential of Transdermal Nicotine in Early Parkinson's Disease in Germany and the USA	Parkinson's Disease	Drug: nicotine transdermal patch	James BOYD MD	Michael J. Fox Foundation for Parkinson's Research;Parkinson Study Group (PSG);International Parkinson Fonds (IPF);German Parkinson Study Group (GPS);German Parkinson Society (DPG);Philipps-University Marburg, Germany	Active, not recruiting	30 Years	N/A	Both	160	Phase 2	United States;Germany
5	EUCTR2010-020299-42-DE (EUCTR)	30/08/2011	26/04/2011	A study in U.S. and Germany to show if patients with an early stage of Parkinson's disease could be treated with a nicotine patch. In this study the nicotine patch is being compared to a placebo patch. The placebo patch is identical in appearance to the nicotine patch but does not contain any active ingredients.	A randomized, placebo-controlled, double-blind, multi-center trial to assess the disease-modifying potential of transdermal nicotine in early Parkinson's disease in Germany and the USA (NIC-PD) - NIC-PD	Early PD subjects within 18 months of diagnosis and not expected to require dopamine agonist or levodopa therapy for 1 year, with Hoehn and Yahr stage <2, with stable (>2 months) MAO-B inhibitor therapy allowed MedDRA version: 16.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Nicotinell 17,5 mg/24-Stunden-Pflaster Product Name: Nicotinell Other descriptive name: NICOTINE Trade Name: Nicotinell 35 mg/24-Stunden-Pflaster Product Name: Nicotinell Other descriptive name: NICOTINE	Philipps-University Marburg	NULL	Not Recruiting			Female: yes Male: yes	160	Phase 2	United States;Germany
6	NCT01216904 (ClinicalTrials.gov)	October 2010	6/10/2010	Nicotine Treatment of Impulsivity in Parkinson's Disease	Nicotine Treatment of Impulsivity in Parkinson's Disease: A Pilot Study	Parkinson's Disease	Drug: nicotine patch;Drug: placebo	University of Vermont	Parkinson's Disease Foundation;The Parkinson Study Group	Recruiting	18 Years	N/A	Both	20	Phase 4	United States
7	NCT00957918 (ClinicalTrials.gov)	October 2009	11/8/2009	Study of NP002 in Subjects With Idiopathic Parkinson's Disease to Treat Dyskinesias Due to Levodopa Therapy	Randomized, Double-Blind, Parallel Group, Placebo Controlled Safety, Tolerability and Efficacy Study of NP002 in Subjects With Idiopathic Parkinson's Disease With Dyskinesias Due to Levodopa Therapy	Parkinson's Disease	Drug: nicotine;Other: placebo comparator	Neuraltus Pharmaceuticals, Inc.	NULL	Completed	30 Years	83 Years	Both	65	Phase 1/Phase 2	United States
8	NCT00873392 (ClinicalTrials.gov)	February 2009	31/3/2009	Efficacy of Transdermal Nicotine, on Motor Symptoms in Advanced Parkinson's Disease	Efficacy of Transdermal Nicotine, on Motor Symptoms in Advanced Parkinson's Disease(One Daily Administration).A Controlled Randomised Study, in Two Parallel Groups and Single Blind in 40 Patients.	Idiopathic Parkinson's Disease	Drug: Transdermal nicotine;Other: Usual drug treatment of Parkinson's disease	Assistance Publique - Hôpitaux de Paris	NULL	Completed	35 Years	70 Years	Both	40	Phase 2	France
9	EUCTR2008-001336-13-FR (EUCTR)	16/07/2008	09/06/2008	Effet de la Nicotine transdermique sur les symptomes moteurs de la maladie de Parkinson avancée (une administration quotidienne) .Etude contrôlée, randomisée, en deux groupes parallèles et en simple insu sur 40 patients. - NICOPARK2	Effet de la Nicotine transdermique sur les symptomes moteurs de la maladie de Parkinson avancée (une administration quotidienne) .Etude contrôlée, randomisée, en deux groupes parallèles et en simple insu sur 40 patients. - NICOPARK2	Maladie Parkinson MedDRA version: 8.1;Level: PT;Classification code 10061536;Term: Parkinson's disease	Trade Name: Nicorette 5 mg/ 16 h Product Name: Nicorette 5 mg/ 16 h INN or Proposed INN: Nicotine Product Name: Nicorette 10mg/ 16 h INN or Proposed INN: Nicotine Product Name: Nicorette 15 mg/ 16 h INN or Proposed INN: Nicotine	ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			France

先頭へ

13. 多発性硬化症／視神経脊髄炎

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05046535 (ClinicalTrials.gov)	September 1, 2021	5/9/2021	The Effect of Cigarette Smoke on Sleep Quality and Physical Activity in People With Multiple Sclerosis	The Effect of Cigarette Smoke on Sleep Quality and Physical Activity in People With Multiple Sclerosis	Multiple Sclerosis	Behavioral: Sleep quality and physical activity;Genetic: Nicotine dependence;Diagnostic Test: Nicotine and cotinine serum levels;Behavioral: Smoking	University of Jordan	NULL	Recruiting	18 Years	N/A	All	80		Jordan

84. サルコイドーシス

臨床試験数 : 149 / 薬物数 : 202 - (DrugBank : 78) / 標的遺伝子数 : 66 - 標的パスウェイ数 : 169

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02265874 (ClinicalTrials.gov)	January 12, 2015	10/10/2014	Nicotine Treatment for Pulmonary Sarcoidosis: A Clinical Trial Pilot Study	Nicotine Treatment for Pulmonary Sarcoidosis: A Clinical Trial Pilot Study	Sarcoidosis	Drug: Habitrol;Drug: Placebo to Habitrol	Ohio State University	The Cleveland Clinic	Completed	18 Years	75 Years	All	57	Phase 1/Phase 2	United States
2	NCT00701207 (ClinicalTrials.gov)	July 2008	17/6/2008	Study of Nicotine Patches in Patients With Sarcoidosis	Modulation of Pulmonary Sarcoidosis by Nicotinic Acetylcholine Receptors	Pulmonary Sarcoidosis	Drug: nicotine patch	Elliott Crouser MD	American Thoracic Society	Completed	18 Years	N/A	All	64	Early Phase 1	United States

先頭へ